Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Human herpesvirus 1 DNA polymerase

8

Thymidine kinase

8

purine nucleotide biosynthetic process

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1982

8

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cold sores

8

Genital herpes

8

Herpes simplex infection

8

Herpes zoster infections

8

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Burroughs Wellcome Fund

8

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

FDA UNII

9

PUBCHEM

9

EPA CompTox

7

SMS_ID

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

DERMATOLOGICALS

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIVIRALS FOR SYSTEMIC USE

2

ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIRECT ACTING ANTIVIRALS

2

ANTIINFECTIVES

1

CHEMOTHERAPEUTICS FOR TOPICAL USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Nucleosides and nucleotides excl. reverse transcriptase inhibitors

2

Antivirals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ACYCLOVIR

X4HES1O11F

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

2-AMINO-6-CHLOROPURINE

83V03P835E

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

purine nucleotide biosynthetic process

Acyclovir Sodium Dihydrate

TZT3J8XU9F

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR

MZ1IW7Q79D

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE MONOHYDRATE

JF64RVR4E3

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

ACYCLOVIR SODIUM

927L42J563

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE DIHYDRATE

A7JO128919

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE

G447S0T1VC

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

DESCICLOVIR

BHM1XXA2EZ

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1